Outcome of the Board meeting held on 25th May, 2026

Net loss reportedEBITDA margin compressionExceptional itemResults restatedResults View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹732.10

prior close

₹706.80

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-5.8% vs market

Pharmaceuticals peers, median of 165sector+0.2%-5.3% vs sector

On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+0.0

15m

+0.6

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.7-5.8+0.2-5.3

Next day

-10.5+0.7-11.2-0.1-10.4

-11.6+0.0-11.7-0.3-11.3

-12.4-1.1-11.3-1.3-11.0

-13.1+0.0-13.1-1.2-11.9

-15.0+0.3-15.3-1.5-13.5

-14.0+1.1-15.1-0.6-13.4

15d

-11.8+4.9-16.6-0.3-11.5

-7.3+5.3-12.7+3.1-10.4

-6.7+6.9-13.6+4.1-10.8

+14.6+11.9+2.7+7.1+7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs Board approved audited FY26 results (standalone and consolidated) ending March 31, 2026. Standalone revenue grew marginally by 1.5% to Rs. 179,755 lakhs from Rs. 177,135 lakhs. However, net profit declined sharply by 31.5% to Rs. 17,620 lakhs from Rs. 25,735 lakhs in FY25, impacted by higher finance costs (Rs. 4,690 vs Rs. 2,563 lakhs), increased depreciation, and foreign exchange losses. The Board declared a final dividend of Rs. 2 per share (40% on Rs. 5 face value). An exceptional item of Rs. 279.49 lakhs was recorded for new labour code provisions. The company restated Q3 FY26 figures due to a previously omitted forward contract fair value adjustment of Rs. 2,972.94 lakhs. Auditors issued unmodified (clean) opinions. Two senior management personnel were designated.

Likely market impact

The sharp 31.5% decline in net profit despite flat revenue growth signals margin compression and higher financial costs, which may concern shareholders. However, the clean audit opinion and dividend declaration provide some comfort.